Prime Medicine Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) 84-3097762 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 60 First Street, Cambridge, MA (Address of principal executive offices)(Zip code) (617) 465-0013(Registrant’s telephone number, including area code) Not applicable(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of April 30, 2026, the registrant had 180,617,451 shares of common stock, par value $0.00001 per share, outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains express or implied statements which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934,as amended, or the Exchange Act. All statements, other than statements of historical facts, contained in this Quarterly Report on Form10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs,prospects, plans, and objectives of management, are forward-looking statements, which are based on management’s belief andassumptions and on information currently available to our management. These statements involve substantial risks, assumptions anduncertainties. The words “anticipate,” “believe,” “envision,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “predict,”“project,” “strategy,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate,” “vision” and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifyingwords. The forward-looking statements in this Quarterly Report on Form 10-Q include statements about: •the initiation, timing, progress and results of our research and development programs, product candidates, and ongoing andfuture preclinical studies and future clinical trials;•our ability to demonstrate, and the timing of, preclinical proof-of-conceptin vivofor multiple programs;•our ability to advance any current and future product candidates that we may identify and successfully complete any clinicaltrials, including the manufacture of any such product candidates;•our ability to pursue our areas of focus and any other additional programs we may advance;•our ability to quickly leverage programs within our initial target indications and to progress additional programs to furtherdevelop our pipeline;•the timing of our investigational new drug, or IND, application submissions;•the ability of our Prime Editing technology to address unmet medical needs in patients;•the implementation of our strategic plans for our business, programs and technology;•the scope and duration of protection we are able to establish and maintain for intellectual property rights covering our PrimeEditing technology;•developments related to our competitors and our industry;•our ability to leverage the clinical, regulatory, and manufacturing advancements made by gene therapy and gene editingprograms to accelerate our clinical trials and approval of product candidates;•our ability to maintain existing collabo